Community-genotype methicillin-resistant Staphylococcus aureus skin and soft tissue infections in Latin America: a systematic review.

Szczegóły
Abstrakt

Tytuł:: Community-genotype methicillin-resistant Staphylococcus aureus skin and soft tissue infections in Latin America: a systematic review.
Autorzy:: Leme RCP; Universidade Federal de São Paulo (UNIFESP), Departamento de Doenças Infecciosas, Laboratório Especial de Microbiologia Clínica (LEMC), São Paulo, SP, Brazil. Electronic address: .
Bispo PJM; Harvard Medical School, Infectious Diseases Institute, Department of Ophthalmology, Massachusetts, United States.
Salles MJ; Universidade Federal de São Paulo (UNIFESP), Departamento de Doenças Infecciosas, Laboratório Especial de Microbiologia Clínica (LEMC), São Paulo, SP, Brazil; Santa Casa de São Paulo, Faculdade de Ciências Médicas, São Paulo, SP, Brazil.
Źródło:: The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases [Braz J Infect Dis] 2021 Jan-Feb; Vol. 25 (1), pp. 101539. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji:: Journal Article; Review; Systematic Review
Język:: English
Imprint Name(s):: Publication: 2010- : Rio de Janeiro : Elsevier Editora
Original Publication: Salvador, Bahia, Brazil : Contexto, c1997-
MeSH Terms:: Community-Acquired Infections*/drug therapy
Community-Acquired Infections*/epidemiology
Methicillin-Resistant Staphylococcus aureus*/genetics
Soft Tissue Infections*/drug therapy
Soft Tissue Infections*/epidemiology
Staphylococcal Infections*/drug therapy
Staphylococcal Infections*/epidemiology
Staphylococcal Skin Infections*/drug therapy
Staphylococcal Skin Infections*/epidemiology
Anti-Bacterial Agents/therapeutic use ; Argentina ; Brazil ; Genotype ; Humans ; Latin America/epidemiology
References:: J Antimicrob Chemother. 2017 Feb;72(2):372-375. (PMID: 27798212)
Antimicrob Agents Chemother. 2017 Sep 22;61(10):. (PMID: 28760895)
Rev Chilena Infectol. 2017 Oct;34(5):487-490. (PMID: 29488592)
Biomedica. 2014 Apr;34 Suppl 1:163-9. (PMID: 24968048)
PLoS One. 2012;7(6):e38576. (PMID: 22745670)
Rev Chilena Infectol. 2009 Oct;26(5):406-12. (PMID: 19915748)
Emerg Microbes Infect. 2016 Dec 21;5(12):e127. (PMID: 27999423)
N Engl J Med. 2006 Aug 17;355(7):666-74. (PMID: 16914702)
Emerg Infect Dis. 2013 Jan;19(1):123-5. (PMID: 23260279)
Ann Clin Microbiol Antimicrob. 2014 Jul 02;13:25. (PMID: 24990470)
Nat Rev Microbiol. 2009 Sep;7(9):629-41. (PMID: 19680247)
Int J Evid Based Healthc. 2015 Sep;13(3):147-53. (PMID: 26317388)
J Antimicrob Chemother. 2020 May 1;75(5):1071-1086. (PMID: 32016348)
Braz J Infect Dis. 2017 Mar - Apr;21(2):185-189. (PMID: 27875687)
J Clin Microbiol. 2006 Jan;44(1):192-200. (PMID: 16390969)
PLoS One. 2013 Nov 20;8(11):e78303. (PMID: 24324543)
BMJ. 2009 Jul 21;339:b2700. (PMID: 19622552)
J Infect Dis. 2005 Oct 1;192(7):1196-200. (PMID: 16136462)
Clin Microbiol Infect. 2016 May;22(5):451-5. (PMID: 26851655)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
Int J Infect Dis. 2019 Oct;87:60-66. (PMID: 31330321)
Clin Infect Dis. 2009 Dec 15;49(12):1861-7. (PMID: 19911971)
J Hosp Infect. 2006 Jul;63(3):330-6. (PMID: 16713018)
Infect Genet Evol. 2013 Mar;14:401-5. (PMID: 23340226)
Eur J Clin Microbiol Infect Dis. 2016 Aug;35(8):1285-95. (PMID: 27177754)
Braz J Microbiol. 2015 Mar 04;45(4):1401-7. (PMID: 25763047)
Int J Med Microbiol. 2013 Mar;303(2):76-83. (PMID: 23369303)
Epidemiol Infect. 2017 Oct;145(13):2817-2826. (PMID: 28803587)
Rev Soc Bras Med Trop. 2017 Nov-Dec;50(6):833-838. (PMID: 29340463)
PLoS One. 2011;6(10):e25716. (PMID: 22022439)
Int J Infect Dis. 2013 May;17(5):e339-42. (PMID: 23266336)
Int J Infect Dis. 2015 Jan;30:156-60. (PMID: 25486009)
PLoS One. 2012;7(1):e30487. (PMID: 22291965)
Int J Antimicrob Agents. 2007 Nov;30(5):469-71. (PMID: 17683914)
Emerg Med J. 2015 Oct;32(10):800-3. (PMID: 25552545)
PLoS One. 2014 Mar 24;9(3):e92537. (PMID: 24663818)
Lancet Infect Dis. 2005 Dec;5(12):751-62. (PMID: 16310147)
Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):281-6. (PMID: 17345057)
Emerg Infect Dis. 2005 Jun;11(6):973-6. (PMID: 15963301)
J Clin Microbiol. 2008 May;46(5):1826-31. (PMID: 18322068)
PLoS One. 2013 Aug 23;8(8):e73434. (PMID: 24058415)
Arch Argent Pediatr. 2008 Oct;106(5):397-403. (PMID: 19030638)
Rev Argent Microbiol. 2018 Jul - Sep;50(3):244-248. (PMID: 29336909)
J Antimicrob Chemother. 2018 Jan 01;73(1):212-222. (PMID: 29045648)
Clin Microbiol Rev. 2018 Sep 12;31(4):. (PMID: 30209034)
JAMA. 2007 Oct 17;298(15):1763-71. (PMID: 17940231)
Int J Med Microbiol. 2014 Nov;304(8):1086-99. (PMID: 25240872)
Rev Soc Bras Med Trop. 2013 Jan-Feb;46(1):34-8. (PMID: 23563822)
J Infect Dev Ctries. 2013 Jan 15;7(1):10-6. (PMID: 23324815)
Contributed Indexing:: Keywords: CA-MRSA; CG-MRSA; Community-onset SSTI; Genetic lineages
Substance Nomenclature:: 0 (Anti-Bacterial Agents)
Entry Date(s):: Date Created: 20210219 Date Completed: 20210323 Latest Revision: 20220824
Update Code:: 20240105
PubMed Central ID:: PMC9392117
DOI:: 10.1016/j.bjid.2021.101539
PMID:: 33607082
: Czasopismo naukowe

Full Text Finder

Background: Community-genotype methicillin-resistant Staphylococcus aureus (CG-MRSA) emerged in the 1990s as a global community pathogen primarily involved in skin and soft tissue infections (SSTIs) and pneumonia. To date, the CG-MRSA SSTI burden in Latin America (LA) has not been assessed.
Objective: The main objective of this study was to report the rate and genotypes of community-genotype methicillin-resistant Staphylococcus aureus (CG-MRSA) causing community-onset skin and soft tissue infections (CO-SSTIs) in LA over the last two decades. In addition, this research determined relevant data related to SSTIs due to CG-MRSA, including risk factors, other invasive diseases, and mortality.
Data Sources: Relevant literature was searched and extracted from five major databases: Embase, PubMed, LILACS, SciELO, and Web of Science.
Methods: A systematic review was performed, and a narrative review was constructed.
Results: An analysis of 11 studies identified epidemiological data across LA, with Argentina presenting the highest percentage of SSTIs caused by CG-MRSA (88%). Other countries had rates of CG-MRSA infection ranging from 0 to 51%. Brazil had one of the lowest rates of CG-MRSA SSTI (4.5-25%). In Argentina, being younger than 50 years of age and having purulent lesions were predictive factors for CG-MRSA CO-SSTIs. In addition, the predominant genetic lineages in LA belonged to sequence types 8, 30, and 5 (ST8, ST30, and ST5).
Conclusion: There are significant regional differences in the rates of CG-MRSA causing CO-SSTIs. It is not possible to conclude whether or not CG-MRSA CO-SSTIs resulted in more severe SSTI presentations or in a higher mortality rate.
(Copyright © 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.)

Informacja